Neal D. Shore, MD, Managing Partner, Atlantic Urology Clinics, Director, CPI, Carolina Urologic Research Center, discusses enzalutamide, a well tolerated oral therapy.
Neal D. Shore, MD
Advertisement
Articles by Neal D. Shore, MD
Dr. Neal Shore, from the Atlantic Urology Clinics, Discusses the Enzalutamide (MDV3100) AFFIRM Trial
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
5